Laser device and imaging analysis maker Hamilton Thorne said today it picked up Mass.-based Embryotech Laboratories for $7.25 million. Get the full story at our sister site, Medical Design & Outsourcing.
Hamilton Thorne Inc.
Fujifilm Medical Systems names new COO, CMO | Personnel Moves
Fujifilm Holdings (TSE:4901) said its Fujifilm Medical Systems U.S.A. subsidiary lured an Accuray (NSDQ:ARAY) executive and a physician from the University of Southern California to its executive roster effective Sept. 28. The Stamford, Conn.-based company said Johann Fernando, formerly Accuray’s vice president & general manager, was named to be its operations chief. Dr. Diku Mandavia, who has […]
Thoratec kills it in Q1, Wall Street shrugs | Earnings Roundup
Thoratec (NSDQ:THOR) started today up 7.2% as investors reacted to its stellar 1st-quarter numbers, but by the time the market closed THOR shares had fallen back to Earth to close at $34.46, down 0.1%.
The heart pump maker posted profits of $25.5 million, or 43¢ per diluted share, on sales of $126.8 million for the 3 months ended March 31.
FDA clears Ethicon’s 1st surgical set docs can assemble inside the body | Regulatory Roundup
Johnson & Johnson (NYSE:JNJ) Ethicon Endo-Surgery won FDA clearance for the 1st surgical instruments that can be assembled and disassembled inside the body during surgery.
Varian and Siemens launch global radiosurgery deal | Wall Street Beat
Ortho stocks up on strong Q2 prelims for Biomet | Earnings Roundup
Shares of orthopedic device makers are up this morning after bellwether Biomet Inc. reported preliminary sales numbers indicating 3.8% growth for its fiscal second quarter.
Hamilton Thorne names new CEO | Personnel Moves
Laser-based lab equipment maker Hamilton Thorne Inc. (TSX-V: HTL) has named company president David Wolf as CEO. Wolf takes over the post from company co-founder Meg Spencer, who will remain with Hamilton Thorne as chairman of the board and a chief strategic advisor.
Wolf, who helped take the company public, has been president of the Hamilton Thorne since 2009 and will continue to hold that role along with the additional CEO responsibilities.
NeuroPace set to land at least $49M in latest round | Funding Roundup
NeuroPace, which is developing an implantable device to treat epilepsy and other neurological disorders, is on the verge of closing a large financing round, according to a regulatory filing
The Mountain View, Calif.-based firm has drummed up $49.1 million of a hoped-for $61.9 million round, according to the filing. A slew of names linked to venture capital firms are listed on the filing, from the likes of Kleiner Perkins Caufield & Byers, New Enterprise Associates, Angel Medical Systems, Cutlass Capital and Domain Associates.
MassDevice podcast: Hamilton Thorne CEO Meg Spencer
Laser-based lab equipment maker Hamilton Thorne Inc. (CVE:HTL) derives a major part of its revenues from the life sciences R&D market. CEO Meg Spencer says that requires the company to surf the leading edge of several life science research waves, including stem cells and regenerative medicine.
The Beverly, Mass.-based company looks to help solve some of the problems scientists encounter as they develop their research on stem cells into regenerative medicine techniques. Those often involve the growth of millions — or even billions — of cells, so anything that can accelerate or automate that process is vital to innovation in the space.
